Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06533553 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

Study acronym: SUSPIRE-1
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 14, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Apr 2025 to Oct 2025
    • Study completion date: Jun 2025 to Dec 2025
    • Site details revised at 23 of 23 sites
    v10
  2. Study sites: 17 to 23v9
  3. Study sites: 15 to 17v8
  4. Study sites: 14 to 15v7
  5. Study sites: 13 to 14v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 11 to 13v5
  2. Site details revised at 2 of 11 sitesv4
  3. Study sites: 3 to 11v3
  4. Eligibility criteria shortened, about 258 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study title shortened, about 4 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Areteia Therapeutics
2 trials monitored
See all monitored trials
COPD
1,119 trials monitored
See 34 trials at risk
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Trial Details
NCT Number NCT06533553
Lead Sponsor Areteia Therapeutics
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov